stars 1 stars 2 stars 3

LineaRx, Inc. (an Applied DNA Sciences, Inc. (NASDAQ: APDN) company) delivers enzymatically produced LinearDNA™ as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity, and scalability to support the next generation of nucleic acid-based therapies. Manufactured by a proprietary, large-scale polymerase chain reaction (‘PCR’)-based manufacturing platform, LinearDNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences. LinearDNA is relevant to a broad array of advanced therapeutics, including mRNA production, DNA vaccines, cell and gene therapies, as well as numerous veterinary medicine applications. Formed in 2018 to commercialize our parent company’s 20+ years of experience and leadership in enzymatic DNA production, LinearRx stands ready to deliver a new generation of DNA for the next generation of medicines. LineaRx, We are DNA Made Simple.

LineaRx, Inc. Questions

The LineaRx, Inc. annual revenue was $5.8 million in 2026.

Eric Vega is the Production Director of LineaRx, Inc..

1 people are employed at LineaRx, Inc..

LineaRx, Inc. is based in Stony Brook, New York.

The NAICS codes for LineaRx, Inc. are [32541, 3254, 32, 325, 325414].

The SIC codes for LineaRx, Inc. are [283, 28].

Top LineaRx, Inc. Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users